Anthem Biosciences Q3FY26: Revenue ₹4,232 Mn with EBITDA Margin at 41.8%
Anthem Biosciences announced Q3FY26 results with revenue of ₹4,232 Mn and EBITDA margin at 41.8%, while nine-month revenue reached ₹15,134 Mn showing 11.2% growth. The company demonstrated strong margin expansion and operational efficiency despite quarterly revenue decline, with management expressing confidence in strong year-end performance.
*this image is generated using AI for illustrative purposes only.
Anthem Biosciences has announced its unaudited consolidated financial results for Q3FY26 and nine months ended December 31, 2025, showing mixed quarterly performance with improved operational efficiency. The pharmaceutical CRDMO demonstrated strong margin expansion despite revenue challenges during the quarter.
Q3FY26 Financial Performance
The company reported consolidated revenue from operations of ₹4,232 Mn for Q3FY26, compared to ₹4,978 Mn in Q3FY25, representing a 15.0% year-on-year decline. The quarterly net profit stood at ₹928 Mn with PAT margins at 20.3%, down from ₹1,243 Mn in the corresponding quarter last year.
| Financial Metric: | Q3FY26 | Q3FY25 | YoY Change |
|---|---|---|---|
| Revenue from Operations: | ₹4,232 Mn | ₹4,978 Mn | (15.0%) |
| EBITDA: | ₹1,907 Mn | ₹1,839 Mn | 3.7% |
| EBITDA Margin: | 41.8% | - | - |
| Profit After Tax: | ₹928 Mn | ₹1,243 Mn | (25.3%) |
| PAT Margin: | 20.3% | - | - |
Business Segment Performance
The CRDMO business segment delivered ₹3,332 Mn in revenues for Q3FY26, declining 19.4% from ₹4,135 Mn in Q3FY25. The Specialty Ingredients segment showed positive growth with revenues of ₹899 Mn, up 6.7% from ₹843 Mn in the previous year's quarter. Other income increased significantly by 37.3% to ₹335 Mn compared to ₹244 Mn in Q3FY25.
Nine-Month Performance Highlights
For the nine months ended December 31, 2025, Anthem Biosciences demonstrated strong overall performance with consolidated revenue from operations of ₹15,134 Mn, marking an 11.2% increase from ₹13,614 Mn in 9MFY25.
| 9MFY26 Metrics: | Current Period | Previous Period | Growth |
|---|---|---|---|
| Revenue from Operations: | ₹15,134 Mn | ₹13,614 Mn | 11.2% |
| EBITDA: | ₹6,712 Mn | ₹5,473 Mn | 22.6% |
| EBITDA Margin: | 41.5% | - | - |
| Profit After Tax: | ₹4,020 Mn | ₹3,686 Mn | 9.1% |
| PAT Margin: | 24.8% | - | - |
Exceptional Items and Labour Code Impact
The company recorded an exceptional item of ₹254 Mn in Q3FY26 related to the new Labour Code implementation. Following the Government of India's notification of four new Labour Codes on November 21, 2025, Anthem Biosciences made provisions as recommended by the Institute of Chartered Accountants of India. The profit before tax after exceptional items was ₹1,305 Mn for the quarter.
Management Commentary and Outlook
Commenting on the results, Ajay Bhardwaj, Chairman, MD and CEO stated that the 9MFY26 performance showed steady progress with EBITDA growing at 23% and PBT before exceptional items growing around 20%. He noted that while quarterly revenue performance was influenced by a higher base from the same quarter last year, margin improvement neutralized the revenue shortfall. The company maintains confidence in delivering a strong finish to the financial year with robust underlying demand.
Historical Stock Returns for Anthem Biosciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +3.73% | +4.56% | -4.06% | -16.54% | -14.03% | -14.03% |
20
